Skip to main content
Back
WXIBF logo

WuXi Biologics (Cayman) Inc.

Data quality: 100%
WXIBF
OTC Healthcare Biotechnology
$4.60
$0.00 (0.00%)
Mkt Cap: 19.01B
Also listed as WXXWY OTC
Day Range
$4.60 $5.26
52-Week Range
$2.26 $5.61
Volume
32,250
50D / 200D Avg
$4.71 / $4.34
Prev Close
$4.60

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (631 peers)

Metric Stock Sector Median
P/E 4.0 0.2
P/B 0.4 3.0
ROE % 10.7 3.6
Net Margin % 22.5 3.8
Rev Growth 5Y % 19.9 9.9
D/E 0.1 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2029 $0.00
$0.00 – $0.00
 38.61B 0
FY2028 $2.04
$1.93 – $2.22
 35.93B 1
FY2027 $1.55
$1.46 – $1.69
 30.30B 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-24 $0.09 $0.09 -3.8%
2025-08-19 $0.06 $0.08 +24.1%
2025-03-25 $0.06 $0.06 -0.1%
2024-08-21 $0.06 $0.05 -14.1%
2024-03-26 $0.04 $0.04 +4.5%
2023-06-30 $0.08 $0.07 -5.1%
2023-03-22 $0.06 $0.06 +14.5%
2022-08-17 $0.40 $0.09 -78.4%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Key Takeaways

Revenue grew 19.85% annually over 5 years — strong growth
Earnings grew 42.48% over the past year
ROE of 10.73% — decent returns on equity
Net margin of 22.53% shows strong profitability
Debt/Equity of 0.07 — conservative balance sheet
Generating 1.29B in free cash flow

Growth

Revenue Growth (5Y)
19.85%
Revenue (1Y)13.67%
Earnings (1Y)42.48%
FCF Growth (3Y)N/A

Quality

Return on Equity
10.73%
ROIC9.64%
Net Margin22.53%
Op. Margin30.50%

Safety

Debt / Equity
0.07
Current Ratio3.14
Interest Coverage46.46

Valuation

P/E Ratio
3.98
Forward P/E3.51
P/B Ratio0.40
EV/EBITDA1.99
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13.67% Revenue Growth (3Y) 11.63%
Earnings Growth (1Y) 42.48% Earnings Growth (3Y) 18.60%
Revenue Growth (5Y) 19.85% Earnings Growth (5Y) 8.99%
Profitability
Revenue (TTM) 21.23B Net Income (TTM) 4.78B
ROE 10.73% ROA 7.50%
Gross Margin 45.98% Operating Margin 30.50%
Net Margin 22.53% Free Cash Flow (TTM) 1.29B
ROIC 9.64% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.07 Current Ratio 3.14
Interest Coverage 46.46
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 3.98 Forward P/E 3.51
P/B Ratio 0.40 P/S Ratio 0.90
PEG Ratio 0.55 Forward PEG N/A
EV/EBITDA 1.99 Fwd EV/EBITDA 1.29
Forward P/S 0.73 Fwd Earnings Yield 28.49%
FCF Yield 6.77%
Market Cap 19.01B Enterprise Value 12.90B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 21.23B 18.68B 17.03B 15.27B 10.29B
Net Income 4.78B 3.36B 3.40B 4.42B 3.39B
EPS (Diluted) 1.12 0.78 0.77 1.01 0.77
Gross Profit 9.76B 7.65B 6.83B 6.72B 4.83B
Operating Income 6.47B 4.97B 4.45B 4.34B 3.19B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 63.73B 56.98B 56.58B 49.56B 44.03B
Total Liabilities 10.66B 11.50B 12.56B 13.35B 11.33B
Shareholders' Equity 47.27B 41.82B 40.33B 35.05B 32.28B
Total Debt 3.11B 4.94B 4.56B 4.42B 4.30B
Cash & Equivalents 9.22B 8.28B 9.67B 6.40B 9.00B
Current Assets 26.14B 23.57B 21.20B 18.47B 19.53B
Current Liabilities 8.31B 8.62B 7.64B 9.32B 8.26B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#375 of 826
45
Growth Price/Sales Ratio Focus (Ken Fisher)
#469 of 619
19

Recent Activity

Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 26, 2026
Exited Defensive Investing (Benjamin Graham)
Mar 26, 2026
Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026